SST antagonists conjugated with radioisotopes became a promising tool in nuclear medicine after Mihaela Ginj and co-workers [56] showed that they are better than agonists for the in vivo targeting of tumours with sstr2 and sstr3 in tumour-bearing mouse models. Here, SST is linked to neoplasm.